Temmune Therapeutics

Mechelen ·KBO/BCE: BE 0776.938.722

Loading dossier…

Year closed	Due by	Filed	Variance	Reference
31-12-2025	31-07-2026	07-04-2026	115 d early	2026-00077831
31-12-2024	31-07-2025	18-07-2025	13 d early	2025-00291423
31-12-2023	31-07-2024	26-03-2024	127 d early	2024-00052073
31-12-2022	31-07-2023	28-06-2023	33 d early	2023-00195077

Line item	Code	2025
Balance sheet, Assets
TOTAL ASSETS	20/58	€3.43M
Fixed assets	21/28	€1.74M
Intangible fixed assets	21	€1.74M
Current assets	29/58	€1.70M
Amounts receivable within one year	40/41	€35k
Cash & bank	54/58	€1.46M
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€3.43M
Equity	10/15	€2.01M
Contributions / capital	10/11	€4.35M
Accumulated profits (losses)	14	€-2.33M
Amounts payable	17/49	€1.42M
Amounts payable after one year	17	€1.10M
Amounts payable within one year	42/48	€320k
Trade debts payable within one year	44	€320k
Income statement
Gross operating margin	9900	€-377k
Operating result	9901	€-2.27M
Financial income	75	€4k
Financial charges	65	€7k
Result before taxes	9903	€-2.27M
Income taxes	67/77	€-59k
Net result for the period	9904	€-2.21M
Result to be appropriated	9905	€-2.21M

Statutory auditor	IRE/IBR number	Tenure
BDO Bedrijfsrevisoren bvCurrent Company auditor · represented by Gert Maris	-	23-09-2024 → present
BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISESCurrent Statutory auditor · represented by Gert Maris	-	30-09-2024 → present

Summary

NACE primary	Vervaardiging van geneesmiddelen(21201)
Legal form	Public limited company(014)
Incorporation	08-11-2021
Status	Active
Postal code	2800

Legal nameNL	Temmune Therapeutics
AbbreviationNL	TemmuneTx